Physician profile
Danielle Mejias
NPI 1811665789
$1,045.40
in general payments reported to CMS, 2019-2025
24 companies · $418 in 2025
The $418 reported for 2025 was more than what 79% of Community Health (Nurse Practitioner) providers received nationally (typical 2025 total: $139).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.71 · 2023: $155 · 2024: $461 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $174.60 | 2023-2025 | Wegovy, Sogroya |
| Lilly USA, LLC | $167.18 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $86.58 | 2024-2025 | Inspire |
| Antares Pharma, INC. | $72.02 | 2024-2025 | Xyosted |
| Dexcom, INC. | $57.46 | 2024-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $52.79 | 2024-2025 | Cequr Simplicity |
| Sequel Med Tech, LLC | $41.44 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $36.44 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.65 | 2024-2025 | Jardiance |
| Itamar Medical INC | $34.42 | 2024 | Watchpatone |
| Radius Health, INC. | $33.05 | 2025 | Tymlos |
| Avadel Cns Pharmaceuticals, LLC | $28.66 | 2024 | Lumryz |
| Abbott Laboratories | $24.14 | 2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $23.76 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $22.78 | 2024 | Crysvita |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $19.83 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $19.83 | 2024 | |
| Jazz Pharmaceuticals INC. | $18.09 | 2025 | |
| Ascensia Diabetes Care US INC. | $18.06 | 2024 | |
| Ibsa Pharma INC. | $16.61 | 2023 | Tirosint, Licart |
| Abbvie INC. | $16.37 | 2025 | |
| Fisher & Paykel Healthcare INC | $16.19 | 2025 | Fisher & Paykel Healthcare |
| Amgen INC. | $15.36 | 2024 | Prolia, Evenity |
| Insulet Corporation | $14.09 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mejias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.